STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents

Activists are up in arms about a Biden administration R&D deal with Gilead Sciences that they claim could hinder access to HIV prevention drugs. They obtained the settlement details, which reveal how the deal prioritizes patent protections over public health needs. Critics argue that this could limit the availability of affordable medications, making it harder for those at risk of HIV to access crucial prevention tools. The controversy underscores a broader debate about balancing pharmaceutical innovation with the imperative to make life-saving drugs accessible.